Sarah J. Jefferies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah J. Jefferies has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Neil Gunn Burnet
Proton Centre, The Christie NHS Foundation Trust, Manchester, UK
8 shared publications R. Jena
5 shared publicationsF. Harris
3 shared publicationsR.J. Benson
3 shared publicationsC. Watts
2 shared publications- Daniel J. Scoffings
From the Department of Clinical Neurosciences (M.Y.T., S.N., K.S., R.H., H.S.M.), University of Cambridge; Department of Radiology (D.S.), Addenbrooke's Hospital; and National Clinic for Ataxia Telangiectasia, Papworth Hospital NHS Foundation Trust (A.E.H.), Cambridge, United Kingdom
2 shared publications
Latest Publications
- Open Access
An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma
Background Glioblastoma (GBM) is the commonest primary malignant brain tumour in adults and effective treatment options are limited. Combining local chemotherapy with enhanced surgical resection using 5-aminolevulinic acid (5-ALA) could improve outcomes. Here we assess the safety and feasibility of combining BCNU wafers with 5-ALA-guided surgery. Methods We conducted a multicentre feasibility study of 5-ALA with BCNU wafers followed by standard-of-care chemoradiotherapy (chemoRT) in patients with suspected GBM. Patients judged suitable for radical resection were administered 5-ALA pre-operatively and BCNU wafers at the end resection. Post-operative treatment continued as per routine clinical practice. The primary objective was to establish if combining 5-ALA and BCNU wafers is safe without compromising patients from receiving standard chemoRT. Results Seventy-two patients were recruited, sixty-four (88.9%) received BCNU wafer implants, and fifty-nine (81.9%) patients remained eligible following formal histological diagnosis. Seven (11.9%) eligible patients suffered surgical complications but only two (3.4%) were not able to begin chemoRT, four (6.8%) additional patients did not begin chemoRT within 6 weeks of surgery due to surgical complications. Eleven (18.6%) patients did not begin chemoRT for other reasons (other toxicity (n = 3), death (n = 3), lost to follow-up/withdrew (n = 3), clinical decision (n = 1), poor performance status (n = 1)). Median progression-free survival was 8.7 months (95% CI: 6.4–9.8) and median overall survival was 14.7 months (95% CI: 11.7–16.8). Conclusions Combining BCNU wafers with 5-ALA-guided surgery in newly diagnosed GBM patients is both feasible and tolerable in terms of surgical morbidity and overall toxicity. Any potential therapeutic benefit for the sequential use of 5-ALA and BCNU with chemoRT requires further investigation with improved local delivery technologies.
Open AccessAn Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma
Background Glioblastoma (GBM) is the commonest primary malignant brain tumour in adults and effective treatment options are limited. Combining local chemotherapy with enhanced surgical resection using 5-aminolevulinic acid (5-ALA) could improve outcomes. Here we assess the safety and feasibility of combining BCNU wafers with 5-ALA-guided surgery. Methods We conducted a multicentre feasibility study of 5-ALA with BCNU wafers followed by standard-of-care chemoradiotherapy (chemoRT) in patients with suspected GBM. Patients judged suitable for radical resection were administered 5-ALA pre-operatively and BCNU wafers at the end resection. Post-operative treatment continued as per routine clinical practice. The primary objective was to establish if combining 5-ALA and BCNU wafers is safe without compromising patients from receiving standard chemoRT. Results Seventy-two patients were recruited, sixty-four (88.9%) received BCNU wafer implants, and fifty-nine (81.9%) patients remained eligible following formal histological diagnosis. Seven (11.9%) eligible patients suffered surgical complications but only two (3.4%) were not able to begin chemoRT, four (6.8%) additional patients did not begin chemoRT within 6 weeks of surgery due to surgical complications. Eleven (18.6%) patients did not begin chemoRT for other reasons (other toxicity (n = 3), death (n = 3), lost to follow-up/withdrew (n = 3), clinical decision (n = 1), poor performance status (n = 1)). Median progression-free survival was 8.7 months (95% CI: 6.4–9.8) and median overall survival was 14.7 months (95% CI: 11.7–16.8). Conclusions Combining BCNU wafers with 5-ALA-guided surgery in newly diagnosed GBM patients is both feasible and tolerable in terms of surgical morbidity and overall toxicity. Any potential therapeutic benefit for the sequential use of 5-ALA and BCNU with chemoRT requires further investigation with improved local delivery technologies.
- Open Access
- 4 May 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 84
Identifying risk factors for L’Hermitte’s sign after IMRT for head and neck cancer
L’Hermitte’s sign (LS) after chemoradiotherapy for head and neck cancer appears related to higher spinal cord doses. IMRT plans limit spinal cord dose, but the incidence of LS remains high. One hundred seventeen patients treated with TomoTherapy™ between 2008 and 2015 prospectively completed a side-effect questionnaire (VoxTox Trial Registration: UK CRN ID 13716). Baseline patient and treatment data were collected. Radiotherapy plans were analysed; mean and maximum spinal cord dose and volumes receiving 10, 20, 30 and 40 Gy were recorded. Dose variation across the cord was examined. These data were included in a logistic regression model. Forty two patients (35.9%) reported LS symptoms. Concurrent weekly cisplatin did not increase LS risk (p = 0.70, OR = 1.23 {95% CI 0.51–2.34}). Of 13 diabetic participants (9 taking metformin), only 1 developed LS (p = 0.025, OR = 0.13 {95% CI 0.051–3.27}). A refined binary logistic regression model showed that patients receiving unilateral radiation (p = 0.019, OR = 2.06 {95% CI 0.15–0.84}) were more likely to develop LS. Higher V40Gy (p = 0.047, OR = 1.06 {95% CI 1.00–1.12}), and younger age (mean age 56.6 vs 59.7, p = 0.060, OR = 0.96 {95% CI 0.92–1.00}) were associated with elevated risk of LS, with borderline significance. In this cohort, concomitant cisplatin did not increase risk, and LS incidence was lower in diabetic patients. Patient age and dose gradients across the spinal cord may be important factors.
- 4 May 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 84
Open AccessIdentifying risk factors for L’Hermitte’s sign after IMRT for head and neck cancer
L’Hermitte’s sign (LS) after chemoradiotherapy for head and neck cancer appears related to higher spinal cord doses. IMRT plans limit spinal cord dose, but the incidence of LS remains high. One hundred seventeen patients treated with TomoTherapy™ between 2008 and 2015 prospectively completed a side-effect questionnaire (VoxTox Trial Registration: UK CRN ID 13716). Baseline patient and treatment data were collected. Radiotherapy plans were analysed; mean and maximum spinal cord dose and volumes receiving 10, 20, 30 and 40 Gy were recorded. Dose variation across the cord was examined. These data were included in a logistic regression model. Forty two patients (35.9%) reported LS symptoms. Concurrent weekly cisplatin did not increase LS risk (p = 0.70, OR = 1.23 {95% CI 0.51–2.34}). Of 13 diabetic participants (9 taking metformin), only 1 developed LS (p = 0.025, OR = 0.13 {95% CI 0.051–3.27}). A refined binary logistic regression model showed that patients receiving unilateral radiation (p = 0.019, OR = 2.06 {95% CI 0.15–0.84}) were more likely to develop LS. Higher V40Gy (p = 0.047, OR = 1.06 {95% CI 1.00–1.12}), and younger age (mean age 56.6 vs 59.7, p = 0.060, OR = 0.96 {95% CI 0.92–1.00}) were associated with elevated risk of LS, with borderline significance. In this cohort, concomitant cisplatin did not increase risk, and LS incidence was lower in diabetic patients. Patient age and dose gradients across the spinal cord may be important factors.
- Open Access
- 1 January 2018
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 8, 12-16
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
- 1 January 2018
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 8, 12-16
Open AccessPARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
- Open Access
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S289
OC-0543: Acute toxicity with helical IGIMRT for head and neck cancer: Unilateral vs bilateral nodal irradiation
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S289
Open AccessOC-0543: Acute toxicity with helical IGIMRT for head and neck cancer: Unilateral vs bilateral nodal irradiation
- 1 November 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1067) , 20160392
Fast imaging employing steady-state acquisition (FIESTA) MRI to investigate cerebrospinal fluid (CSF) within dural reflections of posterior fossa cranial nerves
Objective:There is no consensus approach to covering skull base meningeal reflections—and cerebrospinal fluid (CSF) therein—of the posterior fossa cranial nerves (CNs VII–XII) when planning radiotherapy (RT) for medulloblastoma and ependymoma. We sought to determine whether MRI and specifically fast imaging employing steady-state acquisition (FIESTA) sequences can answer this anatomical question and guide RT planning.Methods:96 posterior fossa FIESTA sequences were reviewed. Following exclusions, measurements were made on the following scans for each foramen respectively (left, right); internal acoustic meatus (IAM) (86, 84), jugular foramen (JF) (83, 85) and hypoglossal canal (HC) (42, 45). A protocol describes measurement procedure. Two observers measured distances for five cases and agreement was assessed. One observer measured all the remaining cases.Results:IAM and JF measurement interobserver variability was compared. Mean measurement difference between observers was −0.275 mm (standard deviation 0....
- 1 November 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1067) , 20160392
Fast imaging employing steady-state acquisition (FIESTA) MRI to investigate cerebrospinal fluid (CSF) within dural reflections of posterior fossa cranial nerves
Objective:There is no consensus approach to covering skull base meningeal reflections—and cerebrospinal fluid (CSF) therein—of the posterior fossa cranial nerves (CNs VII–XII) when planning radiotherapy (RT) for medulloblastoma and ependymoma. We sought to determine whether MRI and specifically fast imaging employing steady-state acquisition (FIESTA) sequences can answer this anatomical question and guide RT planning.Methods:96 posterior fossa FIESTA sequences were reviewed. Following exclusions, measurements were made on the following scans for each foramen respectively (left, right); internal acoustic meatus (IAM) (86, 84), jugular foramen (JF) (83, 85) and hypoglossal canal (HC) (42, 45). A protocol describes measurement procedure. Two observers measured distances for five cases and agreement was assessed. One observer measured all the remaining cases.Results:IAM and JF measurement interobserver variability was compared. Mean measurement difference between observers was −0.275 mm (standard deviation 0....
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi132
CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Background: Failure of drugs to cross the blood brain barrier (BBB) can be a major reason for treatment failure for patients with brain tumours. For most patients who don't respond to treatment, it is not known whether this is due to inadequate drug concentrations in the tumour, or due to drug resistance. Preliminary data suggest that low-dose radiotherapy may disrupt the BBB, and could facilitate increased drug delivery into brain tumours. Afatinib is a potent, irreversible inhibitor of EGFR / HER2 / HER4 and takes approximately 8 days to achieve steady-state concentrations in cancer patients. CamBMT1 has been designed to investigate the delivery of afatinib into brain mets and whether this might be enhanced by low dose-radiotherapy.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi132
CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Background: Failure of drugs to cross the blood brain barrier (BBB) can be a major reason for treatment failure for patients with brain tumours. For most patients who don't respond to treatment, it is not known whether this is due to inadequate drug concentrations in the tumour, or due to drug resistance. Preliminary data suggest that low-dose radiotherapy may disrupt the BBB, and could facilitate increased drug delivery into brain tumours. Afatinib is a potent, irreversible inhibitor of EGFR / HER2 / HER4 and takes approximately 8 days to achieve steady-state concentrations in cancer patients. CamBMT1 has been designed to investigate the delivery of afatinib into brain mets and whether this might be enhanced by low dose-radiotherapy.
- Open Access
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115, S273
OC-0560: FIESTA MRI to investigate CSF around lower cranial nerve roots; implications for radiotherapy planning
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115, S273
Open AccessOC-0560: FIESTA MRI to investigate CSF around lower cranial nerve roots; implications for radiotherapy planning
- Open Access
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115, S726
EP-1346: Volume reduction in the CTV of glioblastoma from editing to intracranial anatomical boundaries
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115, S726
Open AccessEP-1346: Volume reduction in the CTV of glioblastoma from editing to intracranial anatomical boundaries
- 23 April 2013
- Published by Elsevier in Clinical Oncology
- Vol. 25 (7) , 391-393
High Grade Glioma — The Arrival of the Molecular Diagnostic Era for Patients over the Age of 65 Years in the UK
- 23 April 2013
- Published by Elsevier in Clinical Oncology
- Vol. 25 (7) , 391-393
High Grade Glioma — The Arrival of the Molecular Diagnostic Era for Patients over the Age of 65 Years in the UK
- Open Access
- 1 March 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106, S257
PO-0669: Promising outcomes using helical arc therapy for radical treatment of oropharyngeal cancer
- 1 March 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 106, S257
Open AccessPO-0669: Promising outcomes using helical arc therapy for radical treatment of oropharyngeal cancer